An investigator-sponsored, placebo-controlled, multicenter Phase II trial to investigate RNS60 in patients with amyotrophic lateral sclerosis (ALS)

Trial Profile

An investigator-sponsored, placebo-controlled, multicenter Phase II trial to investigate RNS60 in patients with amyotrophic lateral sclerosis (ALS)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs RNS 60 (Primary) ; RNS 60 (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 19 Sep 2017 According to the data published in the ALS association, this trial is lead by neurologists Dr. Ettore Beghi (LEFT), at IRCCS Mario Negri Institute for Pharmacological Research in Milan; and Dr. Letizia Mazzini (RIGHT), at the University Hospital of Novara in Novara, Italy; and Dr. Sabrina Paganoni, at Massachusetts General Hospital in Boston.
    • 19 Sep 2017 According to the data published in the ALS association, the first patient was dosed in mid-July 2017.
    • 19 Sep 2017 Status changed from planning to recruiting according to data published in the ALS association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top